The EGFR inhibitor erlotinib has been used as a monotherapy for patients with non-small cell lung cancer (NSCLC) and combined with gemcitabine for patients with pancreatic cancer to prolong their survival [37, 38]. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.